Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults

NCT03239483 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Dapivirine gel
DRUG: Placebo gel

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)